A nontrivial differential diagnosis in COVID-19 pandemic: a case report and literary review of amiodarone-induced interstitial pneumonia.
Luigi CappannoliAlessandro TelescaRoberto ScacciavillaniEdoardo PetrolatiAndrea SmargiassiAlessia RabiniMassimo MassettiFilippo CreaNadia AspromontePublished in: Future cardiology (2020)
Amiodarone is a drug commonly used to treat and prevent cardiac arrhythmias, but it is often associated with several adverse effects, the most serious of which is pulmonary toxicity. A 79-year-old man presented with respiratory failure due to interstitial pneumonia during the COVID-19 pandemic. The viral etiology was nevertheless excluded by repeated nasopharyngeal swabs and serological tests and the final diagnosis was amiodarone-induced organizing pneumonia. The clinical and computed tomography findings improved after amiodarone interruption and steroid therapy. Even during a pandemic, differential diagnosis should always be considered and pulmonary toxicity has to be taken into account in any patient taking amiodarone and who has new respiratory symptoms.
Keyphrases
- respiratory failure
- computed tomography
- sars cov
- high glucose
- extracorporeal membrane oxygenation
- pulmonary hypertension
- diabetic rats
- mechanical ventilation
- oxidative stress
- drug induced
- coronavirus disease
- magnetic resonance imaging
- stem cells
- left ventricular
- positron emission tomography
- endothelial cells
- emergency department
- community acquired pneumonia
- intensive care unit
- atrial fibrillation
- mesenchymal stem cells
- heart failure
- physical activity
- bone marrow
- depressive symptoms
- dual energy
- magnetic resonance
- stress induced